Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Notice Regarding the Presentation of HGF Clinical Data Analysis Results at the ASIA Annual Scientific Meeting Hosted by the American Spinal Injury Association

The company announced that the results of a post hoc analysis of the completed Phase III clinical trial for spinal cord injury are scheduled to be presented at an international conference. The presentation is also scheduled to report a comparison with the Phase I/II trial.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

oremepermin alfa (development code: KP-100IT)Recombinant human HGF protein
Applicable field (uses covered by this announcement)

Acute spinal cord injury and severe cervical spinal cord injury

Launch date24 April 2026–26 April 2026 (scheduled conference dates) / Presentation scheduled for 26 April 2026, 9:00–9:10 (local time)
Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

The company is supporting the conference as a Silver Sponsor.

CounterpartyAmerican Spinal Injury Association (ASIA)

The American Spinal Injury Association, an organization that hosts international academic conferences in the field of spinal cord injury.

Location (as indicated in this announcement)

San Antonio, Texas, USA (conference venue)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

National Spinal Cord Injury Statistical Center, Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026

Announced details
ItemDetails
Names of Products / Services Coveredoremepermin alfa (development code: KP-100IT), Recombinant human HGF protein
CounterpartyAmerican Spinal Injury Association (ASIA)
Counterparty overviewThe American Spinal Injury Association, an organization that hosts international academic conferences in the field of spinal cord injury.
Relationship with the CompanyThe company is supporting the conference as a Silver Sponsor.
Launch date24 April 2026–26 April 2026 (scheduled conference dates) / Presentation scheduled for 26 April 2026, 9:00–9:10 (local time)
Applicable areaAcute spinal cord injury and severe cervical spinal cord injury
LocationSan Antonio, Texas, USA (conference venue)
SourceNational Spinal Cord Injury Statistical Center, Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To raise awareness of oremepermin alfa through the conference presentation and promote its development in North America in addition to domestic development.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Presentation of HGF Clinical Data Analysis Results at the ASIA Annual Scientific Meeting Hosted by the American Spinal Injury Association | Kringle Pharma,Inc. (4884) timely disclosure | Komori